Experts believe that the industry has the potential to grow at an accelerated 15-20 per cent CAGR for the next 10 years to reach between USD 49 billion to USD 74 billion in 2020.
"The industry has seen many regulatory interventions over the last one year which will require careful consideration by pharma companies as they plan their future strategies," said Sujay Shetty, Executive Director, India Pharmaceutical and Life Sciences Industry Leader, PwC.
"The challenge for us is to make sure that we get lot of innovative medicines to our country for untreated clinical needs, as we have enough producers for molecules in the most competitive market," he said, adding industry needs to climb up on innovation graph.
This year, the New Drug Advisory Committee (NDAC) has approved only nine drugs for clinical trials.
According to PwC, emerging markets will be the next major growth drivers for the global pharma industry with more than 40 per cent of incremental growth coming from emerging economies in the next decade.
As per PwC estimates, the total expenditure on healthcare in these markets is likely to grow from USD 205 billion to USD 499 billion by 2020, with most markets expected to grow at double digit rates.
By 2020, the BRIC countries alone are going to account for 33 per cent of world's GDP, that is up 25 per cent from 2009, said PwC.
In 2011, worldwide sales of medicines reached USD 1.08 trillion with an increase of 7.8 per cent over the previous year. It is expected to be worth USD 1.5 trillion by 2020, the report titled 'Indian Pharma Inc.-Gearing up for the next level of growth' said.
The per capita spend on healthcare in US is USD 8,000 compared to USD 54 per head in India, PwC said.
With the critical market of US driving the growth, USD 148 billion worth of patent expiries are expected between 2012 and 2018, it added.
The medical technology sector, which plays a vital role in the delivery of healthcare services in India was pegged at USD 2.75 billion in 2008.
It is expected to reach USD 14 billion in 2020 at a CAGR of around 15 per cent, according to industry analysts and PwC estimates.
Over the past year, there have been interventions at regulatory level, which shall require careful considerations.
There are changes being discussed in the revised proposal, called the Draft National Pharmaceutical Pricing Policy (NPPP) 2011, which seeks to increase price control by expanding the span of control from 74 to 348 drugs in the National List of Essential Medicines(NLEM), including 654 formulations.